CRF Health’s Platform Selected in Phase III Diabetes Trial
Published on:
CRF Health, a provider of eCOA solutions for the life sciences industry, announced its TrialMax® eCOA platform has been selected by a sponsor to capture more than 4.6 million data points via an integrated medical device in a Phase III diabetes program. The program encompasses 3,000 patients across 450 sites in 28 countries using diabetes care devices and patient diaries. Read the full release.
CRF Health, a provider of eCOA solutions for the life sciences industry, announced its TrialMax® eCOA platform has been selected by a sponsor to capture more than 4.6 million data points via an integrated medical device in a Phase III diabetes program. The program encompasses 3,000 patients across 450 sites in 28 countries using diabetes care devices and patient diaries.
